在人造门手术和HF患者的中期心脏结局在CSP之后的EF中跨越EF
Peng Li1, Xiao-Xiao Jiang1, Yi-Heng Yang1
1Department of Cardiology, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
Pacing and clinical electrophysiology : PACE
|June 5, 2025
概括
导电系统节奏 (CSP) 是对假体门手术和心力衰竭患者的安全和可行的选择. 这种节拍方法促进了逆心脏重塑,并降低了心脏起器诱导的心肌病变的风险,超过25%的心力衰竭患者的减排部分患者实现了正常化.
科学领域:
- 心脏病学 心脏病学
- 心脏电生理学 心脏电生理学
- 心脏衰竭管理的管理
背景情况:
- 导电系统节奏 (CSP) 在假体门手术 (PVS) 和心力衰竭 (HF) 患者的临床结果尚未得到充分证实.
- 这种人群在节奏方面存在独特的挑战,原因是之前的心脏手术和潜在的心脏病.
研究的目的:
- 评估CSP在PVS和HF患者中的可行性,安全性和临床影响.
- 评估CSP对心脏结构和功能在不同的左心室喷射率 (LVEF) 类别的影响.
主要方法:
- 连续一系列的患者与心房阻塞后PVS和HF史经历CSP被录取.
- 根据LVEF分析了结果:减少 (HFrEF),轻度减少 (HFmrEF) 和保存 (HFpEF).
- 关键的评估包括LVEF,左心室末端透气直径 (LVEDD),左心房直径和纽约心脏协会 (NYHA) 类.
主要成果:
- 在93.75%的患者中,CSP是成功的.
- 所有LVEF队列都显示LVEDD有所改善.
- HFrEF组在LVEF,左心脏直径和NYHA等级上显示出显著的改善.
- 在HFmrEF/HFpEF组中没有观察到任何恶化.
- 缺少风湿性心脏病 (RHD) 是 26.47% 的 HFrEF 患者完全正常化 LVEF/LVEDD 的独立预测因素.
- 在平均随访25.49个月期间,没有发生心脏穿孔,血栓形成或心脏起器诱导的心肌病 (PICM) 等重大并发症.
结论:
- CSP是一种可行且安全的节奏策略,用于患有HF的PVS患者.
- 在所有LVEF类别中,CSP促进心脏逆向重塑并减轻PICM风险.
- 非RHD病因学预测HFrEF患者的显著部分心脏功能的完全正常化.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:29Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
01:22Heart Failure Drugs: β-Blockers
446
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
446
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:22Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30